Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1016/j.pnpbp.2018.06.002 http://hdl.handle.net/11449/171118 |
Resumo: | Cannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in several neuropsychiatric disorders including depression. CBD treatment has shown significant antidepressant-like effects in different rodent preclinical models. However, the mechanisms involved in CBD-induced antidepressant effects are still poorly understood. Therefore, this work aimed at investigating the participation of serotonin (5-HT) and/or noradrenaline (NA) in CBD-induced antidepressant-like effects in the forced swimming test (FST) by: 1) testing if CBD co-administration with serotonergic (fluoxetine, FLX) or noradrenergic (desipramine, DES) antidepressants would have synergistic effects; and 2) investigating if 5-HT or NA depletion would impair CBD-induced behavioral effects. Results showed that CBD (10 mg/kg), FLX (10 mg/kg) and DES (5 mg/kg) induced antidepressant-like effects in mice submitted to FST. Ineffective doses of CBD (7 mg/kg), when co-administered with ineffective doses of FLX (5 mg/kg) or DES (2.5 mg/kg) resulted in significant antidepressant-like effects, thus implicating synergistic and/or additive mechanisms. Pretreatment with PCPA (an inhibitor of serotonin synthesis: 150 mg/kg, i.p., once per day for 4 days), but not DSP-4 (a noradrenergic neurotoxin: 1 μg/μl, i.c.v., 24 h before the test), reduced monoamine levels in the brain. However, only PCPA treatment abolished CBD-induced behavioral effects in FST, indicating the participation of serotonergic mechanisms. None of the treatments induced locomotor effects. Our results suggest that the antidepressant-like effect induced by CBD in the FST is dependent on serotonin levels in the central nervous system (CNS). |
id |
UNSP_15b155cf62f1fb078ca8bfe55d1e197f |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/171118 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levelsAntidepressantCannabidiolDesipramineFluoxetineNoradrenalineSerotoninCannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in several neuropsychiatric disorders including depression. CBD treatment has shown significant antidepressant-like effects in different rodent preclinical models. However, the mechanisms involved in CBD-induced antidepressant effects are still poorly understood. Therefore, this work aimed at investigating the participation of serotonin (5-HT) and/or noradrenaline (NA) in CBD-induced antidepressant-like effects in the forced swimming test (FST) by: 1) testing if CBD co-administration with serotonergic (fluoxetine, FLX) or noradrenergic (desipramine, DES) antidepressants would have synergistic effects; and 2) investigating if 5-HT or NA depletion would impair CBD-induced behavioral effects. Results showed that CBD (10 mg/kg), FLX (10 mg/kg) and DES (5 mg/kg) induced antidepressant-like effects in mice submitted to FST. Ineffective doses of CBD (7 mg/kg), when co-administered with ineffective doses of FLX (5 mg/kg) or DES (2.5 mg/kg) resulted in significant antidepressant-like effects, thus implicating synergistic and/or additive mechanisms. Pretreatment with PCPA (an inhibitor of serotonin synthesis: 150 mg/kg, i.p., once per day for 4 days), but not DSP-4 (a noradrenergic neurotoxin: 1 μg/μl, i.c.v., 24 h before the test), reduced monoamine levels in the brain. However, only PCPA treatment abolished CBD-induced behavioral effects in FST, indicating the participation of serotonergic mechanisms. None of the treatments induced locomotor effects. Our results suggest that the antidepressant-like effect induced by CBD in the FST is dependent on serotonin levels in the central nervous system (CNS).Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Department of Pharmacology School of Medicine of Ribeirão Preto University of São PauloLaboratory of Pharmacology School of Pharmaceutical Sciences of Araraquara São Paulo State University (UNESP)Center for Interdisciplinary Research on Applied Neurosciences (NAPNA) University of São PauloDepartment of Physics and Chemistry School of Pharmaceutical Sciences of Ribeirão Preto University of São PauloTranslational Neuropsychiatry Unit Department of Clinical Medicine Aarhus UniversityLaboratory of Pharmacology School of Pharmaceutical Sciences of Araraquara São Paulo State University (UNESP)FAPESP: 2015/01955-0; 2012/17626CNPq: 465458/2014-9CNPq: INCT-CNPqUniversidade de São Paulo (USP)Universidade Estadual Paulista (Unesp)Aarhus UniversitySales, Amanda J.Crestani, Carlos C. [UNESP]Guimarães, Francisco S.Joca, Sâmia R.L.2018-12-11T16:53:58Z2018-12-11T16:53:58Z2018-08-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article255-261application/pdfhttp://dx.doi.org/10.1016/j.pnpbp.2018.06.002Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 86, p. 255-261.1878-42160278-5846http://hdl.handle.net/11449/17111810.1016/j.pnpbp.2018.06.0022-s2.0-850487312332-s2.0-85048731233.pdfScopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengProgress in Neuro-Psychopharmacology and Biological Psychiatry1,714info:eu-repo/semantics/openAccess2023-11-16T06:14:08Zoai:repositorio.unesp.br:11449/171118Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T17:52:39.145984Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels |
title |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels |
spellingShingle |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels Sales, Amanda J. Antidepressant Cannabidiol Desipramine Fluoxetine Noradrenaline Serotonin |
title_short |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels |
title_full |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels |
title_fullStr |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels |
title_full_unstemmed |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels |
title_sort |
Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels |
author |
Sales, Amanda J. |
author_facet |
Sales, Amanda J. Crestani, Carlos C. [UNESP] Guimarães, Francisco S. Joca, Sâmia R.L. |
author_role |
author |
author2 |
Crestani, Carlos C. [UNESP] Guimarães, Francisco S. Joca, Sâmia R.L. |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Estadual Paulista (Unesp) Aarhus University |
dc.contributor.author.fl_str_mv |
Sales, Amanda J. Crestani, Carlos C. [UNESP] Guimarães, Francisco S. Joca, Sâmia R.L. |
dc.subject.por.fl_str_mv |
Antidepressant Cannabidiol Desipramine Fluoxetine Noradrenaline Serotonin |
topic |
Antidepressant Cannabidiol Desipramine Fluoxetine Noradrenaline Serotonin |
description |
Cannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in several neuropsychiatric disorders including depression. CBD treatment has shown significant antidepressant-like effects in different rodent preclinical models. However, the mechanisms involved in CBD-induced antidepressant effects are still poorly understood. Therefore, this work aimed at investigating the participation of serotonin (5-HT) and/or noradrenaline (NA) in CBD-induced antidepressant-like effects in the forced swimming test (FST) by: 1) testing if CBD co-administration with serotonergic (fluoxetine, FLX) or noradrenergic (desipramine, DES) antidepressants would have synergistic effects; and 2) investigating if 5-HT or NA depletion would impair CBD-induced behavioral effects. Results showed that CBD (10 mg/kg), FLX (10 mg/kg) and DES (5 mg/kg) induced antidepressant-like effects in mice submitted to FST. Ineffective doses of CBD (7 mg/kg), when co-administered with ineffective doses of FLX (5 mg/kg) or DES (2.5 mg/kg) resulted in significant antidepressant-like effects, thus implicating synergistic and/or additive mechanisms. Pretreatment with PCPA (an inhibitor of serotonin synthesis: 150 mg/kg, i.p., once per day for 4 days), but not DSP-4 (a noradrenergic neurotoxin: 1 μg/μl, i.c.v., 24 h before the test), reduced monoamine levels in the brain. However, only PCPA treatment abolished CBD-induced behavioral effects in FST, indicating the participation of serotonergic mechanisms. None of the treatments induced locomotor effects. Our results suggest that the antidepressant-like effect induced by CBD in the FST is dependent on serotonin levels in the central nervous system (CNS). |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-12-11T16:53:58Z 2018-12-11T16:53:58Z 2018-08-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.pnpbp.2018.06.002 Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 86, p. 255-261. 1878-4216 0278-5846 http://hdl.handle.net/11449/171118 10.1016/j.pnpbp.2018.06.002 2-s2.0-85048731233 2-s2.0-85048731233.pdf |
url |
http://dx.doi.org/10.1016/j.pnpbp.2018.06.002 http://hdl.handle.net/11449/171118 |
identifier_str_mv |
Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 86, p. 255-261. 1878-4216 0278-5846 10.1016/j.pnpbp.2018.06.002 2-s2.0-85048731233 2-s2.0-85048731233.pdf |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Progress in Neuro-Psychopharmacology and Biological Psychiatry 1,714 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
255-261 application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128869576736768 |